Enorama Pharma AB (publ)

Stockholm Stock Exchange ERMA.ST

Enorama Pharma AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 132.66

Enorama Pharma AB (publ) Price to Sales Ratio (P/S) is 132.66 on January 14, 2025, a 11.36% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Enorama Pharma AB (publ) 52-week high Price to Sales Ratio (P/S) is 260.10 on January 31, 2024, which is 96.07% above the current Price to Sales Ratio (P/S).
Enorama Pharma AB (publ) 52-week low Price to Sales Ratio (P/S) is 69.65 on May 30, 2024, which is -47.50% below the current Price to Sales Ratio (P/S).
Enorama Pharma AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 137.28.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: ERMA.ST

Enorama Pharma AB (publ)

CEO	Mr. Daniel Schroder
IPO Date	June 10, 2016
Location	Sweden
Headquarters	Södergatan 3
Employees	5
Sector	Health Care
Industries Pharmaceuticals Tobacco

Description

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.

Key trends

Past 5 years